{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:59:39Z","timestamp":1761541179202},"reference-count":108,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/mbc.0000000000000098","type":"journal-article","created":{"date-parts":[[2014,3,10]],"date-time":"2014-03-10T13:05:45Z","timestamp":1394456745000},"page":"539-552","source":"Crossref","is-referenced-by-count":2,"title":["Promising coagulation factor VIII bypassing strategies for patients with haemophilia A"],"prefix":"10.1097","volume":"25","author":[{"given":"Xunwei","family":"Duan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias: from royal genes to gene therapy.","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-2516.1998.440346.x","article-title":"The molecular basis of haemophilia A.","volume":"4","author":"Peake","year":"1998","journal-title":"Haemophilia"},{"key":"R3-1-20210203","first-page":"340","article-title":"Molecular diagnosis of inherited bleeding disorders and thrombophilia.","volume":"36","author":"Lillicrap","year":"1999","journal-title":"Semin Hematol"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM199203193261205","article-title":"Molecular and cellular biology of blood coagulation.","volume":"326","author":"Furie","year":"1992","journal-title":"N Engl J Med"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis.","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.2830470209","article-title":"Results of secondary prophylaxis in children with severe hemophilia.","volume":"47","author":"Manco-Johnson","year":"1994","journal-title":"Am J Hematol"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1021\/bi00420a030","article-title":"Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells.","volume":"27","author":"Thim","year":"1988","journal-title":"Biochemistry"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"8925","DOI":"10.1073\/pnas.96.16.8925","article-title":"Structure of human factor VIIa and its implications for the triggering of blood coagulation.","volume":"96","author":"Pike","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1160\/TH07-05-0332","article-title":"All posttranslational modifications except propeptide cleavage are required for optimal secretion of coagulation factor VII.","volume":"98","author":"Bolt","year":"2007","journal-title":"Thromb Haemost"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.thromres.2010.01.023","article-title":"Current status on tissue factor activation of factor VIIa.","volume":"125","author":"Persson","year":"2010","journal-title":"Thromb Res"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.thromres.2009.09.014","article-title":"Impaired secretion of carboxyl-terminal truncated factor VII due to an F7 nonsense mutation associated with FVII deficiency.","volume":"125","author":"Tanaka","year":"2010","journal-title":"Thromb Res"},{"key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0037-1963(01)90147-7","article-title":"Recombinant factor VIIa (NovoSeven (R)) as a hemostatic agent.","volume":"38","author":"Hedner","year":"2001","journal-title":"Semin Hematol"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(03)90000-2","article-title":"A cell-based model of coagulation and the role of factor VIIa.","volume":"17","author":"Hoffman","year":"2003","journal-title":"Blood Rev"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/01.ATV.0000031340.68494.34","article-title":"Platelets and thrombin generation.","volume":"22","author":"Monroe","year":"2002","journal-title":"Arterioscl Thromb Vas"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood.V99.1.175","article-title":"Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.","volume":"99","author":"Lisman","year":"2002","journal-title":"Blood"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1046\/j.1538-7836.2003.00242.x","article-title":"The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIIIFIX.","volume":"1","author":"He","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R19-1-20210203","first-page":"328","article-title":"Recombinant human FVIIa dose dependently shortens the bleeding time in a rabbit model of antibody induced hemophilia A.","volume":"S1","author":"Kristensen","year":"1999","journal-title":"Thromb Haemost"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2516.2005.01157.x","article-title":"Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety.","volume":"11","author":"Von Depka","year":"2005","journal-title":"Haemophilia"},{"key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1160\/TH08-07-0434","article-title":"Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.","volume":"100","author":"Hedner","year":"2008","journal-title":"Thromb Haemost"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.thromres.2013.05.027","article-title":"Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect.","volume":"132","author":"Mathijssen","year":"2013","journal-title":"Thromb Res"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1160\/TH09-11-0797","article-title":"Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma.","volume":"104","author":"Johansen","year":"2010","journal-title":"Thromb Haemost"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/mt.2008.117","article-title":"Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.","volume":"16","author":"Ohmori","year":"2008","journal-title":"Mol Ther"},{"key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"65a","DOI":"10.1182\/blood.V110.11.195.195","article-title":"Gene transfer of canine FVIIa results in partial correction of canine hemophilia: a model for FVIIIFIX gene-based bypassing agents.","volume":"110","author":"Margaritis","year":"2007","journal-title":"Blood"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood-2008-07-168377","article-title":"Successful treatment of canine hemophilia by continuous expression of canine FVIIa.","volume":"113","author":"Margaritis","year":"2009","journal-title":"Blood"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2010-09-309732","article-title":"Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.","volume":"117","author":"Margaritis","year":"2011","journal-title":"Blood"},{"key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2003-05-1369","article-title":"Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.","volume":"102","author":"Tranholm","year":"2003","journal-title":"Blood"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymthe.2005.07.151","article-title":"Nonviral gene transfer of factor VII as alternative treatment for hemophilia A.","volume":"11","author":"Chen","year":"2005","journal-title":"Mol Ther"},{"key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/01.ATV.0000257204.82396.2b","article-title":"A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.","volume":"27","author":"Allen","year":"2007","journal-title":"Arterioscl Thromb Vas"},{"key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1365-2516.2011.02536.x","article-title":"Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.","volume":"17","author":"Knudsen","year":"2011","journal-title":"Haemophilia"},{"key":"R32-1-20210203","first-page":"385","article-title":"Prolonged serum half-life of a recombinant fusion protein linking activated coagulation factor VII with albumin (FVIIA-FP) in different preclinical species.","volume":"9","author":"Dickneite","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R33-1-20210203","first-page":"297","article-title":"BAY 86-6150, a novel recombinant factor VIIa variant, has a significantly higher therapeutic index than eptacog alfa (activated) in rabbit bleeding and thrombosis models.","volume":"9","author":"Sim","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood.V118.21.2252.2252","article-title":"A novel FVIIa variant with increased potency and duration of effect compared to wildtype FVIIa. A study in a dog model of hemophilia A.","volume":"118","author":"Pittman","year":"2011","journal-title":"Blood"},{"key":"R35-1-20210203","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/jmedgenet-2011-100195","article-title":"Promoter methylation in coagulation F7 gene influences plasma FVII concentrations and relates to coronary artery disease.","volume":"49","author":"Friso","year":"2012","journal-title":"J Med Genet"},{"key":"R36-1-20210203","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.thromres.2011.02.018","article-title":"Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa.","volume":"128","author":"Karpf","year":"2011","journal-title":"Thromb Res"},{"key":"R37-1-20210203","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejpb.2010.12.037","article-title":"The effect of GlycoPEGylation on the physical stability of human rFVIIa with increasing calcium chloride concentration.","volume":"78","author":"Plesner","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"R38-1-20210203","first-page":"163","article-title":"Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives.","volume":"36","author":"Stennicke","year":"2008","journal-title":"Tierarztliche Praxis Grosstiere"},{"key":"R39-1-20210203","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2516.2009.02121.x","article-title":"Effect of glycoPEGylation on factor VIIa binding and internalization.","volume":"16","author":"Sen","year":"2010","journal-title":"Haemophilia"},{"key":"R40-1-20210203","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1055\/s-0037-1616517","article-title":"Relationship between factor VII activity and cinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.","volume":"86","author":"Santagostino","year":"2001","journal-title":"Thromb Haemost"},{"key":"R41-1-20210203","doi-asserted-by":"crossref","first-page":"13583","DOI":"10.1073\/pnas.241339498","article-title":"Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.","volume":"98","author":"Persson","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-1-20210203","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1016\/S0021-9258(17)34560-X","article-title":"Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI.","volume":"253","author":"Osterud","year":"1978","journal-title":"J Biol Chem"},{"key":"R43-1-20210203","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1050-1738(02)00210-4","article-title":"Structure-function relationships in factor IX and factor IXa.","volume":"13","author":"Schmidt","year":"2003","journal-title":"Trends Cardiovas Med"},{"key":"R44-1-20210203","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.1021\/bi060451h","article-title":"The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation.","volume":"45","author":"Fribourg","year":"2006","journal-title":"Biochemistry"},{"key":"R45-1-20210203","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/j.1460-2075.1988.tb03045.x","article-title":"The role of beta-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX.","volume":"7","author":"Rees","year":"1988","journal-title":"EMBO J"},{"key":"R46-1-20210203","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1074\/jbc.270.24.14325","article-title":"Regulation of the tertiary structure and function of coagulation factor IX by magnesium (II) ions.","volume":"270","author":"Sekiya","year":"1995","journal-title":"J Biol Chem"},{"key":"R47-1-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jmb.2005.04.052","article-title":"Na site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding.","volume":"350","author":"Schmidt","year":"2005","journal-title":"J Mol Biol"},{"key":"R49-1-20210203","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0969-2126(99)80125-7","article-title":"Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding.","volume":"7","author":"Hopfner","year":"1999","journal-title":"Structure"},{"key":"R50-1-20210203","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1074\/jbc.M314011200","article-title":"Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific antifactor IX antibody.","volume":"279","author":"Huang","year":"2004","journal-title":"J Biol Chem"},{"key":"R51-1-20210203","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1016\/S0021-9258(19)69627-4","article-title":"The role of phospholipid and factor VIIIa in the activation of bovine factor X.","volume":"256","author":"van Dieijen","year":"1981","journal-title":"J Biol Chem"},{"key":"R52-1-20210203","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1074\/jbc.M210722200","article-title":"Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop.","volume":"278","author":"Sichler","year":"2003","journal-title":"J Biol Chem"},{"key":"R53-1-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2516.2006.01336.x","article-title":"Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII.","volume":"12","author":"Poon","year":"2006","journal-title":"Haemophilia"},{"key":"R54-1-20210203","first-page":"010","article-title":"Muscle gene therapy for hemophilia.","volume":"S1","author":"Sabatino","year":"2013","journal-title":"J Genet Syn Gene Ther"},{"key":"R55-1-20210203","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood-2011-05-353672","article-title":"Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.","volume":"119","author":"Milanov","year":"2012","journal-title":"Blood"},{"key":"R56-1-20210203","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1093\/emboj\/16.22.6626","article-title":"Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants.","volume":"16","author":"Karl-Peter","year":"1997","journal-title":"EMBO J"},{"key":"R57-1-20210203","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1538-7836.2009.03560.x","article-title":"Factor IX mutants with enhanced catalytic activity.","volume":"7","author":"Hartmann","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R58-1-20210203","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1021\/bi992735q","article-title":"Insertion loo 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII.","volume":"39","author":"Kolkman","year":"2000","journal-title":"Biochemistry"},{"key":"R59-1-20210203","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"R60-1-20210203","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2009-08-239665","article-title":"Prolonged activity of factor IX as a monomeric Fc fusion protein.","volume":"115","author":"Peters","year":"2010","journal-title":"Blood"},{"key":"R61-1-20210203","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua).","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"R62-1-20210203","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1538-7836.2009.03560.x","article-title":"Factor IX mutants with enhanced catalytic activity.","volume":"7","author":"Hartmann","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R63-1-20210203","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","article-title":"Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.","volume":"118","author":"Ostergaard","year":"2011","journal-title":"Blood"},{"key":"R64-1-20210203","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1160\/TH09-04-0255","article-title":"Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.","volume":"102","author":"Metzner","year":"2009","journal-title":"Thromb Haemost"},{"key":"R65-1-20210203","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2010-07-296103","article-title":"Proteolytic antibodies activate factor IX in patients with acquired hemophilia.","volume":"117","author":"Wootla","year":"2011","journal-title":"Blood"},{"key":"R66-1-20210203","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1021\/bi001477q","article-title":"Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.","volume":"39","author":"Adler","year":"2000","journal-title":"Biochemistry"},{"key":"R67-1-20210203","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2010-08-300756","article-title":"Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.","volume":"117","author":"Bunce","year":"2011","journal-title":"Blood"},{"key":"R68-1-20210203","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/pro.5560070401","article-title":"Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes.","volume":"7","author":"Khan","year":"1998","journal-title":"Protein Sci"},{"key":"R69-1-20210203","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1074\/jbc.M802205200","article-title":"The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly.","volume":"283","author":"Toso","year":"2008","journal-title":"J Biol Chem"},{"key":"R70-1-20210203","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1016\/S0021-9258(18)42587-2","article-title":"Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor Xdes-143-191.","volume":"267","author":"Duffy","year":"1992","journal-title":"J Biol Chem"},{"key":"R71-1-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V76.1.1.1","article-title":"Surface-dependent reactions of the vitamin K-dependent enzyme complexes.","volume":"76","author":"Mann","year":"1990","journal-title":"Blood"},{"key":"R72-1-20210203","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev.med.46.1.103","article-title":"Tissue factor pathway inhibitor and the revised theory of coagulation.","volume":"46","author":"Broze","year":"1995","journal-title":"Annu Rev Med"},{"key":"R73-1-20210203","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1016\/S0021-9258(19)84436-8","article-title":"Analysis of the generation and inhibition of activated coagulation factor X in pure systems and in human plasma.","volume":"261","author":"Jesty","year":"1986","journal-title":"J Biol Chem"},{"key":"R74-1-20210203","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2141.1988.tb02405.x","article-title":"A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo.","volume":"69","author":"Giles","year":"1988","journal-title":"Br J Haematol"},{"key":"R75-1-20210203","doi-asserted-by":"crossref","first-page":"41352","DOI":"10.1074\/jbc.M507846200","article-title":"Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas.","volume":"280","author":"Louvain-Quintard","year":"2005","journal-title":"J Biol Chem"},{"key":"R76-1-20210203","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood.V86.11.4153.bloodjournal86114153","article-title":"Procoagulant activity of reversibly acylated human factor Xa.","volume":"86","author":"Wolf","year":"1995","journal-title":"Blood"},{"key":"R77-1-20210203","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0037-1613298","article-title":"The role of factor X activation peptide: a deletion mutagenesis approach.","volume":"88","author":"Rudolph","year":"2002","journal-title":"Thromb Haemost"},{"key":"R78-1-20210203","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/bit.10312","article-title":"Self activating factor X derivative fused to the C terminus of a cellulose binding module: production and properties.","volume":"79","author":"Kwan","year":"2002","journal-title":"Biotechnol Bioeng"},{"key":"R79-1-20210203","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nbt.1995","article-title":"A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.","volume":"29","author":"Ivanciu","year":"2011","journal-title":"Nat Biotechnol"},{"key":"R80-1-20210203","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.0042-9007.2003.00365.x","article-title":"A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.","volume":"85","author":"Tomokiyo","year":"2003","journal-title":"Vox Sang"},{"key":"R81-1-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.thromres.2009.12.010","article-title":"Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIaFX mixture as an alternative bypassing agent.","volume":"125","author":"Nakatomi","year":"2010","journal-title":"Thromb Res"},{"key":"R82-1-20210203","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2516.2011.02548.x","article-title":"Clinical pharmacological study of a plasma derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - phase I trial.","volume":"18","author":"Shirahata","year":"2012","journal-title":"Haemophilia"},{"key":"R83-1-20210203","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/hae.12205","article-title":"A phase II clinical trial of a mixture of plasma derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokineticspharmacodynamics.","volume":"19","author":"Shirahata","year":"2013","journal-title":"Haemophilia"},{"key":"R84-1-20210203","first-page":"291","article-title":"Treatment of inhibitor patients with activated prothrombin complex concentrates.","volume":"150","author":"Penner","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"R85-1-20210203","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/00001721-200210000-00012","article-title":"Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA.","volume":"13","author":"Gallistl","year":"2002","journal-title":"Blood Coagul Fibrin"},{"key":"R86-1-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2004.00935.x","article-title":"FEIBA safety profile in multiple modes of clinical and home-therapy application.","volume":"10","author":"Luu","year":"2004","journal-title":"Haemophilia"},{"key":"R87-1-20210203","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0037-1615363","article-title":"Measurement of active coagulation factors in autoplex-T with colorimetric active site-specific assay technology.","volume":"80","author":"Lundblad","year":"1998","journal-title":"Thromb Haemost"},{"key":"R88-1-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000057293","article-title":"Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors.","volume":"32","author":"Wilde","year":"2002","journal-title":"Pathophysiol Haemost T"},{"key":"R89-1-20210203","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/jth.12197","article-title":"Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness.","volume":"11","author":"Yada","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R90-1-20210203","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000056722","article-title":"Factor Xa and prothrombin: mechanism of action of FEIBA.","volume":"77","author":"Turecek","year":"1999","journal-title":"Vox Sang"},{"key":"R91-1-20210203","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1111\/j.1365-2516.2012.02776.x","article-title":"Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.","volume":"18","author":"Nanishi","year":"2012","journal-title":"Haemophilia"},{"key":"R92-1-20210203","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s002470050122","article-title":"Magnetic resonance imaging of myocardial infarction during prothrombin complex concentrate therapy of hemophilia A.","volume":"27","author":"Gruen","year":"1997","journal-title":"Pediatr Radiol"},{"key":"R93-1-20210203","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2516.2004.00912.x","article-title":"Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.","volume":"10","author":"Schneiderman","year":"2004","journal-title":"Haemophilia"},{"key":"R94-1-20210203","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2516.2012.02748.x","article-title":"Combined treatment with APCC (FEIBA (R)) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience.","volume":"18","author":"Holmstrom","year":"2012","journal-title":"Haemophilia"},{"key":"R95-1-20210203","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2516.2007.01451.x","article-title":"Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience.","volume":"13","author":"Schneiderman","year":"2007","journal-title":"Haemophilia"},{"key":"R96-1-20210203","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2516.2009.02028.x","article-title":"Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.","volume":"15","author":"Martinowitz","year":"2009","journal-title":"Haemophilia"},{"key":"R97-1-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2141.2010.08378.x","article-title":"Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.","volume":"151","author":"Klintman","year":"2010","journal-title":"Br J Haematol"},{"key":"R98-1-20210203","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/blood.V118.21.1178.1178","article-title":"A novel mechanism of enhancing the haemostatic effect in the combination with recombinant factor VIII and activated prothrombin complex concentrate (APCC) in hemophilia A patients with inhibitor.","volume":"118","author":"Yada","year":"2011","journal-title":"Blood"},{"key":"R99-1-20210203","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1055\/s-0037-1613155","article-title":"Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy.","volume":"88","author":"Key","year":"2002","journal-title":"Thromb Haemost"},{"key":"R100-1-20210203","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2516.2002.00626.x","article-title":"Inhibitors: resolving diagnostic and therapeutic dilemmas.","volume":"8","author":"Dimichele","year":"2002","journal-title":"Haemophilia"},{"key":"R101-1-20210203","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"R102-1-20210203","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3121\/cmr.3.4.234","article-title":"Tolerance induction by viral in vivo gene transfer.","volume":"3","author":"Dobrzynski","year":"2005","journal-title":"Clin Med Res"},{"key":"R103-1-20210203","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood.V97.1.107","article-title":"Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.","volume":"97","author":"Gallo-Penn","year":"2001","journal-title":"Blood"},{"key":"R104-1-20210203","first-page":"190","article-title":"Genetics and clinical presentation of haemophilia A and B.","volume":"20","author":"Schwaab","year":"2008","journal-title":"Med Genet-Berlin"},{"key":"R105-1-20210203","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/14712590902729392","article-title":"Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A.","volume":"9","author":"Amy","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"R106-1-20210203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0049-3848(00)00397-2","article-title":"Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.","volume":"101","author":"Elg","year":"2001","journal-title":"Thromb Res"},{"key":"R107-1-20210203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1185\/030079906X80224","article-title":"Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.","volume":"22","author":"Joshi","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R108-1-20210203","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2516.2007.01601.x","article-title":"Single 270g kg-1-dose rFVIIa vs. standard 90g kg-1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.","volume":"14","author":"Young","year":"2008","journal-title":"Haemophilia"},{"key":"R109-1-20210203","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2516.2009.02038.x","article-title":"Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.","volume":"15","author":"Bonnet","year":"2009","journal-title":"Haemophilia"},{"key":"R110-1-20210203","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12325-008-0135-6","article-title":"Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors.","volume":"26","author":"Knight","year":"2009","journal-title":"Adv Ther"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000000098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:21:48Z","timestamp":1620958908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001721-201409000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0000000000000098","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}